|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lam JS, Leppert JT, Belldegrun AS and
Figlin RA: Novel approaches in the therapy of metastatic renal cell
carcinoma. World J Urol. 23:202–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kugel JF and Goodrich JA: Non-coding RNAs:
Key regulators of mammalian transcription. Trends Biochem Sci.
37:144–151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fachel AA, Tahira AC, Vilella-Arias SA,
Maracaja-Coutinho V, Gimba ER, Vignal GM, Campos FS, Reis EM and
Verjovski-Almeida S: Expression analysis and in silico
characterization of intronic long noncoding RNAs in renal cell
carcinoma: Emerging functional associations. Mol Cancer.
12:1402013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhan A and Mandal SS: LncRNA HOTAIR: A
master regulator of chromatin dynamics and cancer. Biochim Biophys
Acta 1856. 151–164. 2015.
|
|
7
|
Cui Y, Zhang F, Zhu C, Geng L, Tian T and
Liu H: Upregulated lncRNA SNHG1 contributes to progression of
non-small cell lung cancer through inhibition of miR-101-3p and
activation of Wnt/β-catenin signaling pathway. Oncotarget.
8:17785–17794. 2017.PubMed/NCBI
|
|
8
|
She K, Yan H, Huang J, Zhou H and He J:
miR-193b availability is antagonized by LncRNA-SNHG7 for
FAIM2-induced tumour progression in non-small cell lung cancer.
Cell Prolif. 51:2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi
K, Gu Y and Fang G: Long non-coding RNA GHET1 promotes gastric
carcinoma cell proliferation by increasing c-Myc mRNA stability.
FEBS J. 281:802–813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou J, Li X, Wu M, Lin C, Guo Y and Tian
B: Knockdown of long noncoding RNA GHET1 inhibits cell
proliferation and invasion of colorectal cancer. Oncol Res.
23:303–309. 2016. View Article : Google Scholar
|
|
11
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weischenfeldt J, Simon R, Feuerbach L,
Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H,
Rausch T, et al: Integrative genomic analyses reveal an
androgen-driven somatic alteration landscape in early-onset
prostate cancer. Cancer Cell. 23:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abell AN and Johnson GL: Implications of
mesenchymal cells in cancer stem cell populations: Relevance to
EMT. Curr Pathobiol Rep. 2:21–26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thiounn N, Mathiot C, Dorval T, Flam TA,
Tartour E, Mosseri V, Zerbib M, Fridman WH and Debre B: Lack of
efficacy of low-dose subcutaneous recombinant interleukin-2 and
interferon-alpha in the treatment of metastatic renal cell
carcinoma. Br J Urol. 75:586–589. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abel EJ and Wood CG: Cytoreductive
nephrectomy for metastatic RCC in the era of targeted therapy. Nat
Rev Urol. 6:375–383. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Faris JE and Michaelson MD: Targeted
therapies: Sunitinib versus interferon-alpha in metastatic RCC. Nat
Rev Clin Oncol. 7:7–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grünwald V, Weikert S, Seidel C, Busch J,
Johannsen A, Fenner M, Reuter C, Ganser A and Johannsen M: Efficacy
of sunitinib re-exposure after failure of an mTOR inhibitor in
patients with metastatic RCC. Onkologie. 34:310–314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao Y, Xu R, Xu X, Zhou Y, Cui L and He X:
Downregulation of lncRNA CASC2 by microRNA-21 increases the
proliferation and migration of renal cell carcinoma cells. Mol Med
Rep. 14:1019–1025. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng
J, Lin W, Huang Q, Li G, Zheng J and Chang C: LncRNA-SARCC
suppresses renal cell carcinoma (RCC) progression via altering the
androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ.
24:1502–1517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong Q, Li O, Zheng W, Xiao WZ, Zhang L,
Wu D, Cai GY, He JC and Chen XM: LncRNA HOTAIR regulates HIF-1α/AXL
signaling through inhibition of miR-217 in renal cell carcinoma.
Cell Death Dis. 8:e27722017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin L, He Y, Tang S and Huang S: LncRNA
GHET1 predicts poor prognosis in hepatocellular carcinoma and
promotes cell proliferation by silencing KLF2. J Cell Physiol.
233:4726–4734. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou HY, Zhu H, Wu XY, Chen XD, Qiao ZG,
Ling X, Yao XM and Tang JH: Expression and clinical significance of
long-non-coding RNA GHET1 in pancreatic cancer. Eur Rev Med
Pharmacol Sci. 21:5081–5088. 2017.PubMed/NCBI
|
|
25
|
Guan ZB, Cao YS, Li Y, Tong WN and Zhuo
AS: Knockdown of lncRNA GHET1 suppresses cell proliferation,
invasion and LATS1/YAP pathway in non small cell lung cancer.
Cancer Biomark. 21:557–563. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song R, Zhang J, Huang J and Hai T: Long
non-coding RNA GHET1 promotes human breast cancer cell
proliferation, invasion and migration via affecting epithelial
mesenchymal transition. Cancer Biomark. 22:565–573. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Savagner P: The epithelial-mesenchymal
transition (EMT) phenomenon. Ann Oncol. 21 Suppl 7:vii89–vii92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tam WL and Weinberg RA: The epigenetics of
epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu ZY, Yu QM, Du YA, Yang LT, Dong RZ,
Huang L, Yu PF and Cheng XD: Knockdown of long Non-coding RNA
HOTAIR suppresses tumor invasion and reverses
Epithelial-mesenchymal transition in gastric cancer. Int J Biol
Sci. 9:587–597. 2013. View Article : Google Scholar : PubMed/NCBI
|
